are relenza sales biting into tami sales???

Outlook
Based on its first-quarter sales, Roche confirms its full-year outlook for 2010. Barring unforeseen events, Roche expects sales in 2010 for the Pharmaceuticals Division and for the Group to increase in the mid-single-digit range in local currencies (excluding Tamiflu). In the Diagnostics Division, full-year sales are expected to grow significantly ahead of the market. Despite an anticipated decrease in Tamiflu sales from 3.2 to 1.2 billion Swiss Francs, Roche is aiming to achieve double-digit Core Earnings per Share growth at constant exchange rates. In addition, by the end of the year Roche expects to have repaid a quarter of the debt raised to finance the Genentech transaction.
''

Judging by this forecast huge decrease in sales in tamipooh I Am guessing my Qtr 1 tip is looking better after this, get ready for take off!!....

Roche must be on the look out for a replacement ... Biota and Lani must be on the radar...

http://www.roche.com/media/media_releases/med-cor-2010-04-15.htm